Pharmacology and Pharmacokinetic Properties of Available Antiretrovirals



Currently recommended antiretrovirals consist of a variety of agents from different drug classes. Differences in mechanism of action result in unique combinations that allow for additive interactions and synergy, leading to increased therapeutic success. However, overlapping toxicities place patients at risk of increased adverse effects such as hepatotoxicity and endocrine abnormalities. A summary of the pharmacological and pharmacokinetic considerations is given in Table 3.1 for currently available nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, integrase inhibitors, and pharmacokinetic enhancers.


Adverse Effect Infectious Disease Protease Inhibitor Reverse Transcriptase Pharmacokinetic Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lexi-comp (2015) Drug information handbook, 24th edn. Lexi-comp, Inc, HudsonGoogle Scholar
  2. 2.
    Piliero PJ (2004) Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 37(Suppl 1):S2–S12CrossRefPubMedGoogle Scholar
  3. 3.
    Tran JQ, Gerber JG, Kerr BM (2001) Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 40(3):207–226CrossRefPubMedGoogle Scholar
  4. 4.
    Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893–905CrossRefPubMedGoogle Scholar
  5. 5.
    Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RMW (2009) Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 48(9):561–574CrossRefPubMedGoogle Scholar
  6. 6.
    Le Tiec C, Barrail A, Goujard C, Taburet A (2005) Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 44(10):1035–1050CrossRefPubMedGoogle Scholar
  7. 7.
    Flexner C (1998) HIV-protease inhibitors. N Eng J Med 338(18):1281–1293CrossRefGoogle Scholar
  8. 8.
    Abel S, Back DJ, Vourvahis M (2009) Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14(5):607–618PubMedGoogle Scholar
  9. 9.
    Cottrell ML, Hadzic T, Kashuba AD (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52(11):981–994CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50(4):229–244CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2016

Authors and Affiliations

  1. 1.College of PharmacyQatar UniversityDohaQatar
  2. 2.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada

Personalised recommendations